News

The companies have also announced research collaboration for the development of five additional gene therapy products in neurological disorders. Benitec’s silence-and-replace gene therapy technology has been designed to deliver a

The Pennsylvania-based cannabinoid-based drug developer reported that the drug, which is delivered via a transdermal patch, could not achieve the target blood levels of 5 to 15ng/ml THC

The regulator has accepted the application for a type II variation to the marketing authorization for Rubracato include maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian

The company will recruit around 450 patients in the double-blind, randomized, placebo-controlled, 48-week safety and efficacy trial. The patients will be randomized 1:1:1 to two different Anavex 2-73

As per terms of the deal, Juniper will purchase all outstanding shares of Juniper by paying $11.50 per share in cash. Juniper’s core businesses include Crinone (progesterone gel)

Aveo said that Novartis informed it that although the AV-380 Program is a key asset, the development delays of the drug and the changes in its management and

AstraZeneca, along with its biologics research and development arm MedImmune, has secured approval from the Japanese ministry of health, labour and welfare for Imfinzi (durvalumab) as maintenance therapy

The agreements have a combined value of $5.9 million and these projects are expected to be substantially completed within a 15-month period. Telix is a biopharmaceutical company specializing

These therapeutic antibodies include ‘blood-brain barrier (BBB)’ penetrating bispecific antibodies (BsAb) (VEGF/undisclosed BBB target BsAb, undisclosed target/undisclosed BBB target BsAb); immune cell engaging bispecific antibodies (4-1BB/undisclosed target BsAb,